Halda Therapeutics, a startup using new cancer-fighting technology developed by serial biotechnology entrepreneur Craig Crews, has raised $126 million in new funding to advance experimental drugs into human testing for prostate and breast cancers, the company said Monday.

Halda Therapeutics公司周一表示，该公司利用系列生物技术企业家克雷格·克鲁斯（CraigCrews）开发的新型抗癌技术，已筹集1.26亿美元新资金，将实验药物推进前列腺癌和乳腺癌的人体检测。

The Series B round extension brings to $202 million the total Halda has raised in support of a drug technology it calls RIPTAC, which uses a dual-acting small molecule drug to spur an interaction between proteins that kills tumor cells. Discovered in Crews’ Yale University laboratories, the RIPTAC technology builds on research that involves “gluing” proteins together inside tumor cells to tag the cells for destruction..

Halda为支持一种名为RIPTAC的药物技术筹集了2.02亿美元的资金，该技术使用双作用小分子药物来刺激杀死肿瘤细胞的蛋白质之间的相互作用。RIPTAC技术是在克鲁斯（Crews）耶鲁大学实验室（Yale University laboratories）发现的，它建立在将肿瘤细胞内的蛋白质“粘合”在一起以标记细胞进行破坏的研究基础上。。

The earlier approach, called “protein degradation,” has been brought forward by startups such as Arvinas, Lycia Therapeutics and Kymera Therapeutics.

早期的方法称为“蛋白质降解”，是由Arvinas，Lycia Therapeutics和Kymera Therapeutics等初创公司提出的。

Halda’s RIPTAC technology holds together a cancer-specific protein to another protein essential to cell function, in turn causing an interaction that halts the essential function and results in cell death.

Halda的RIPTAC技术将一种癌症特异性蛋白质与另一种对细胞功能至关重要的蛋白质结合在一起，从而引起相互作用，从而停止基本功能并导致细胞死亡。

The funding will help Halda advance the experimental prostate cancer drug, code-named HLD‑0915, into the clinic in the first half of 2025. The company presented data from experiments in mice in early 2023, followed up by publication of additional data in a scientific journal earlier this month.

这笔资金将帮助Halda在2025年上半年将代号为HLD-0915的实验性前列腺癌药物推向临床。该公司于2023年初提供了小鼠实验数据，随后在本月早些时候的一份科学期刊上发表了其他数据。

Halda hopes to show that HLD-0915 can help people with metastatic prostate cancer who no longer respond to hormone therapy. In preclinical testing, it was used in models of prostate cancer that were resistant to use of the commonly used drug Xtandi.

哈尔达希望证明，HLD-0915可以帮助那些对激素治疗不再有反应的转移性前列腺癌患者。在临床前测试中，它被用于对常用药物Xtandi产生耐药性的前列腺癌模型中。

“This financing will enable us to bring to patients our oral, selective, and widely applicable cancer cell-killing mechanism that is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,” said Kat Kayser-Bricker, Halda’s chief scientific officer, in a statement..

Halda首席科学官Kat Kayser Bricker在一份声明中表示：“这笔资金将使我们能够为患者提供口服，选择性和广泛适用的癌细胞杀伤机制，旨在克服耐药性，这是目前许多癌症治疗标准的主要缺点。”。。

New investors Deep Track Capital, Frazier Life Sciences, RA Capital Management, Vida Ventures, Boxer Capital and Taiho Ventures took part in the funding round. They were joined by existing investors Canaan Partners, Access Biotechnology, Elm Street Ventures, and Connecticut Innovations.

新投资者Deep Track Capital、Frazier Life Sciences、RA Capital Management、Vida Ventures、Boxer Capital和Taiho Ventures参与了这轮融资。现有投资者包括加拿大合作伙伴、Access Biotechnology、Elm Street Ventures和康涅狄格州创新公司。

As part of the transaction, the company will add to its board of directors Rebecca Luse, of Deep Track Capital; Joe Cabral, of Frazier Life Sciences; Nandita Shangari of RA Capital Management and Arjun Goyal, of Vida Ventures.

作为交易的一部分，公司将在董事会中增加Deep Track Capital的Rebecca Luse；弗雷泽生命科学公司的乔·卡布拉尔；RA Capital Management的Nandita Shangari和Vida Ventures的Arjun Goyal。